Analysts Expect Heron Therapeutics Inc (HRTX) Will Post Earnings of -$0.44 Per Share

Equities analysts predict that Heron Therapeutics Inc (NASDAQ:HRTX) will report earnings of ($0.44) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Heron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.28). Heron Therapeutics reported earnings per share of ($0.97) during the same quarter last year, which suggests a positive year over year growth rate of 54.6%. The firm is expected to announce its next earnings results on Tuesday, February 26th.

On average, analysts expect that Heron Therapeutics will report full-year earnings of ($2.34) per share for the current fiscal year, with EPS estimates ranging from ($2.52) to ($2.18). For the next year, analysts anticipate that the firm will report earnings of ($0.80) per share, with EPS estimates ranging from ($1.44) to $0.03. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The business had revenue of $19.79 million during the quarter, compared to the consensus estimate of $19.84 million. During the same quarter last year, the company earned ($0.77) earnings per share. The firm’s revenue was up 130.9% compared to the same quarter last year.



HRTX has been the subject of a number of research reports. Cantor Fitzgerald set a $50.00 price objective on Heron Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 30th. Zacks Investment Research upgraded Heron Therapeutics from a “sell” rating to a “buy” rating and set a $34.00 price objective for the company in a report on Thursday, October 11th. Stifel Nicolaus initiated coverage on Heron Therapeutics in a report on Thursday, September 13th. They set a “buy” rating and a $55.00 price objective for the company. ValuEngine downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 4th. Finally, BidaskClub downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $52.09.

In related news, Director Kevin C. Tang sold 2,695,000 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total transaction of $96,346,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Kimberly Manhard sold 6,000 shares of the stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $32.07, for a total value of $192,420.00. Following the transaction, the vice president now directly owns 6,000 shares of the company’s stock, valued at $192,420. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,701,494 shares of company stock valued at $96,553,796. 16.20% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of HRTX. Cubist Systematic Strategies LLC acquired a new position in Heron Therapeutics during the second quarter valued at approximately $151,000. Jefferies Group LLC acquired a new position in Heron Therapeutics during the third quarter valued at approximately $202,000. Verition Fund Management LLC acquired a new position in Heron Therapeutics during the third quarter valued at approximately $208,000. Pacer Advisors Inc. acquired a new position in Heron Therapeutics during the third quarter valued at approximately $223,000. Finally, Public Employees Retirement Association of Colorado acquired a new position in Heron Therapeutics during the third quarter valued at approximately $224,000.

NASDAQ:HRTX opened at $27.88 on Friday. The stock has a market cap of $2.18 billion, a P/E ratio of 7.64 and a beta of 1.48. Heron Therapeutics has a 52-week low of $15.00 and a 52-week high of $42.90.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: Fundamental Analysis and Individual Investors

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply